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Abstract
Background:  Mammalian Gli proteins are important transcription factors involved in the
regulation of Sonic hedgehog signal transduction pathway. Association of Gli2 with mammalian
development and human disease led us to study the structure and expression of the human GLI2.
Results: We show that the region encoding GLI2 repressor domain is subject to alternative
splicing in the gonadal tissues and different cell lines. Two major alternatively spliced forms of GLI2
mRNA arise from skipping exon 3 (GLI2∆3) or exons 4 and 5 (GLI2∆4–5). Both forms contain
premature translational stop codons in the GLI2 open reading frame (ORF) starting from exon 2.
Translation of GLI2∆3 and GLI2∆4–5 in vitro, initiated from downstream AUG codons, produced N-
terminally truncated proteins. In Gli-dependent transactivation assay, expression of GLI2∆3 induced
activation of the reporter gene similar to that of the full-length construct (GLI2fl) containing
complete ORF. However, expression of the GLI2∆4–5 resulted in about 10-fold increase in
activation, suggesting that deletion of the major part of repressor domain was responsible for the
enhanced activation of GLI2 protein.
Conclusion: Our data suggest that in addition to proteolytic processing, alternative splicing may
be another important regulatory mechanism for the modulation of repressor and activator
properties of GLI2 protein.
Background
Segment polarity genes induce signaling pathways that
direct morphogenesis by giving cells positional informa-
tion that in turn is translated into appropriate differentia-
tion programs. The Sonic hedgehog (Shh) signaling
pathway is required in many tissues for embryonic pat-
terning, cell proliferation and differentiation [1-3]. Inap-
propriate activation of the pathway drives tumorigenesis
in the skin [4-8] and other tissues [9-11].
The Cubitus interruptus protein (Ci) in Drosophila and Gli
proteins in mammals are the transcriptional effectors of
the Shh signaling pathway. Like in fruit fly, multiple Gli
transcription factors in vertebrates participate in the trans-
duction of Shh signal and may repress transcription of
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Shh target genes [12,13]. Similarly to Ci, Gli2 and Gli3
can be proteolytically processed forming an N-terminal
repressor that is concentrated in the nucleus [12-15].
Interestingly, deletion of N-terminal fragment of mouse
Gli2 containing putative repressor domain altered skin
tumor phenotype [5]. Hedgehog (Hh) signaling controls
Ci protein activity at the post-translational level. In the
absence of the Hh signaling Ci is processed into a trun-
cated repressor form which can inhibit Hh target genes
[16]. Loss of Hh function results in all Ci being converted
into the repressor form [17]. Different in vitro functions of
Gli proteins suggest that Gli2 and Gli3 respond to and are
activated by Shh signaling, whereas Gli1 is a transcrip-
tional target of activated Gli2 and Gli3 [12,18].
Several studies reveal how Gli proteins are regulated in the
cytoplasm through vertebrate protein Supressor of fused
(Sufu), previously identified in flies as having antagonistic
role in Hh signaling [19-21]. Sufu can sequester Gli pro-
teins in the cytoplasm, but can also interact with Gli
bound to DNA. Thus, Sufu is considered to be a key nega-
tive regulator of the Hh signaling pathway in vertebrates
[20]. Targeted disruption of the murine suppressor of
fused gene (Sufu) led to a phenotype that included neural
tube defects and lethality at mid-gestation [22].
It has been proposed that Hh signaling leads to the inhi-
bition of Sufu, deposphorylation of Glis and the produc-
tion of transcriptionally active forms with enhanced
nuclear import [23]. A short motif of four amino acids
(aa), SYGH, is required for the interaction of Sufu with
Gli. The activity of Gli transcription factors with muta-
tions in this motif is no longer suppressed by co-expres-
sion with SUFU [21].
Each Gli has distinct activities that are analogous to the
regulatory properties of Ci [13]. The first studies on mam-
malian Gli genes in vivo revealed the combinatorial action
of genes. In fact, Gli1 and Gli2, but not Gli1 and Gli3 have
extensive overlapping functions [24,25]. Gli2, but not
Gli1, is required for initial Shh signaling and ectopic acti-
vation of Shh pathway [26]. Gli2-/- mice die at birth exhib-
iting defects in floor plate and adjacent interneuron
development, as well as in vertebrae, bones and lungs
[1,3,27,28]. Interestingly, Gli2;Gli3 double mutant mice
develop more severe defects in skeleton and foregut deriv-
atives than either single mutant, indicating that Gli2 and
Gli3  possess both unique and overlapping functions
[3,27]. In addition, loss-of-function mutations in the
human GLI2 gene are associated with a distinctive pheno-
type whose primary features include defective anterior
pituitary formation and pan-hypopituitarism, with or
without overt forebrain cleavage abnormalities [29]. Sim-
ilarly, several disorders of mouse and human develop-
ment, are caused by GLI3  mutations [30,31] and
references therein.
Despite of extensive gene targeting studies, there have
been no comprehensive studies on the structure of the
Gli2 gene. Human GLI2 was originally identified as a Tax-
helper protein (THP) that binds to Tax-responsive ele-
ment in the long terminal repeat of the human T-cell
leukemia virus [32]. However, when compared to orthol-
ogous  Gli2  genes from different species, the human
mRNAs lacked a part of the 5' region encoding the evolu-
tionarily conserved N-terminus of Gli2. Recently, Roessler
et al. [33] have discovered a 5' sequence encoding 328 aa
and showed that this so far undescribed amino-terminal
repressor domain was essential for the dominant negative
activity of the human GLI2. The transcription repression
activity of C-terminally truncated Gli variants has been
demonstrated by two independent studies showing that
Gli2 and Gli3 proteins contained separate transcription
repressor and activator domains [12] which in case of Gli3
were regulated by proteolytic processing [12,14,15]. How-
ever, in contrast to Gli3, overexpressed Gli2 was not proc-
essed efficiently [13]. Thus, the exact mechanism of
repressor generation remains unclear, leaving us with a
question whether mechanisms other than proteolytic
processing may influence the functional activity of Gli2.
To study the potential role of mRNA splicing in genera-
tion of different GLI2 protein variants, we determined the
exon-intron organization of human GLI2 and analyzed
tissue-specific distribution of GLI2 mRNA and its alterna-
tively spliced forms. Here we show that the revised human
GLI2 contains an alternative 5' noncoding exon and its
last coding exon encompasses a 1822 bp-long 3' UTR.
Comparison with the mouse Gli2 gene/mRNA confirmed
the presence of exons 3–6 in the human GLI2 [33]. Two
novel alternatively spliced forms of GLI2  generated by
skipping exon 3, or exons 4 and 5 were detected in ovary
and testis. These forms showed different activator proper-
ties in the GLI-dependent transactivation assay. Our
results suggest that alternative splicing in the 5' terminal
region of human GLI2 mRNA plays an important role in
regulation of GLI2 expression and generation of protein
isoforms with different activities.
Results
Human GLI2 contains four exons encoding amino-
terminal repressor domain
To identify common structural elements of the human
and mouse Gli2 genes, we compared their genomic struc-
tures and mRNAs. Mouse Gli2 gene contains 14 exons
located in about 220 kb region on the chromosome
1E2+3, as revealed by alignment of the mouse Gli2 mRNA
[GenBank: X99104][34] to the corresponding genomic
contig [GenBank: NT_039180](Fig. 1). Extension of theBMC Molecular Biology 2006, 7:13 http://www.biomedcentral.com/1471-2199/7/13
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published mRNA sequence [34] by 180 nucleotides (nt)
in the 5' untranslated region (UTR) and 543 nt in the 3'
UTR using overlapping EST sequences [GenBank:
CN536241 and AW546128/BC031171] generated mRNA
of 6576 nt. The last exon has 1651 nt of 3' UTR and con-
tains a polyadenylation signal ATTAAA, located 15 nt
upstream of the polyA addition site. The location of the
cap site of the mRNA is not known. Mouse Gli2 mRNA has
a coding region of 1544 aa predicting a protein of 165 kD
[34].
To characterize the exon-intron organization of human
GLI2, we aligned human ESTs [GenBank: BM147847,
CN295561, AI822132, BX103004 and AI089685] and
human and mouse Gli2 mRNAs [GenBank: NM_030379
and X99104] to the human genomic contig [GenBank:
NT_022135]. These alignments revealed that, similarly to
the mouse counterpart, human GLI2 consists of 14 exons
spanning 250 kb on the chromosome 2q14 (Fig. 1). Com-
parison between mouse and human Gli2 structures pre-
dicted the presence of exons 3–6 of human GLI2 similar
to those of the mouse Gli2. This conclusion confirms ear-
lier finding of Roessler et al. [33], who demonstrated the
presence of exons 3–6 in the human GLI2  mRNA,
although details of their prediction have not been
described. The complete ORF of human GLI2 starts from
exon 2 and terminates in exon 14 predicting a protein of
1569 aa with molecular weight of 166 kD (Fig. 4). The
predicted protein structure differs from that described by
Roessler et al. [33] by a17 aa sequence (GQVSGHGSCG-
CALPLSQ). This extra sequence is present in the published
protein sequence [GenBank: AAY87165] that is derived
from alternatively spliced GLI2  mRNA [GenBank:
DQ086814] [33]. The respective mRNA is spliced using
alternative acceptor splice site located 51 nt upstream
from the boundary of intron 8 and exon 9. It should be
noted that alternative splicing involving 51 nt deletion/
insertion in the coding region of GLI2 mRNA has been
described previously [32]. Since our RT-PCR reaction
using primers derived from exons 2 and 14 (see Methods)
yielded the major product of 2481 bp lacking the 51 nt in
exon 9, we believe that the GLI2 protein used in our stud-
ies represents the predominant form (1569 aa) of the
human GLI2 protein. In addition, mouse Gli2 mRNA cod-
ing region [34] lacks the respective 51 nt sequence.
GLI2 protein is conserved throughout vertebrate evolu-
tion, showing high degree of sequence identity to its
orthologs from mouse (83%)[34], chicken (68%)[35]
and zebrafish (56%)[36] (IP unpublished data). Conser-
vation of the N-terminus (residues 61–284), containing
putative repressor domain [12], is even more striking –
94% identity with mouse, 87% identity with chicken, and
78% identity with zebrafish (Fig. 2).
GLI2 has two alternative 5' noncoding exons and 
extension in the 3' UTR
Comparison of human and mouse Gli2 transcripts (e.g.
[GenBank: NM_030379 and CN536241] with the human
genomic sequence predicted two alternative 5' noncoding
Exon-intron organization of the human and mouse Gli2 genes Figure 1
Exon-intron organization of the human and mouse Gli2 genes. Gene structures were predicted from the mapping of 
mouse and human GLI2 mRNAs to the corresponding genomic sequences (GenBank reference accession numbers shown on 
the right). Exons (numbered) and introns are shown by vertical and horizontal lines, respectively. Alternative 5' noncoding 
exons in human gene are designated as 1a and 1b. Asterisks indicate exons 3–6, predicted from the comparison of mouse and 
human Gli2 mRNAs and genomic structures, identified by Roessler et al. [33].
** * *
3 4 5 6-13 14 1         2 
1a    1b
Human GLI2
(NT_022135)
Mouse Gli2
(NT_039180)
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exons in the human GLI2 locus, designated exon 1a and
1b (Fig. 1). Exon 1a is highly conserved between human,
mouse (corresponds to exon 1 in mouse Gli2 in Fig. 1), rat
and dog, showing 75–83% identity at the nucleotide level
(data not shown). It is about 60 kb upstream of the exon
2 (the first coding exon). Exon 1b is located about 5 kb
upstream of exon 2 and corresponds to the 5' sequence of
the original GLI2 mRNA, cloned from HTLV-1-infected
Hut102 cells [32]. To determine whether exons 1a and 1b
are transcribed in vivo, we amplified the GLI2 5' region
from human cell line and tissue cDNAs using forward and
reverse primers annealing to exons 1a or 1b and 3, respec-
tively. Amplification products of predicted size and
sequence were obtained for exon 1a (315 bp) as well as
exon 1b (295 bp) using cDNAs derived from ovary, testis,
teratocarcinoma cell line NTera2D1 and human embry-
onic kidney cell line HEK293 (Fig. 3A). This result shows
that both alternative first exons are used in vivo. Although
we did not quantify the level of GLI2 mRNA in different
human tissues, GLI2  transcripts containing exon 1a
seemed to be more abundant than those containing exon
1b. In summary, these results show that human GLI2
Evolutionary conservation of GLI2 Figure 2
Evolutionary conservation of GLI2. ClustalW multiple alignment of Gli2 orthologs from human, mouse, chicken and 
zebrafish species (only N-terminal parts are shown). In the alignment, zebrafish yot protein (encoded by you-too) is shown. 
Su(fu) binding site SYGH is indicated by asterisks. The initiator methionine of human GLI2 defined by Tanimura et al. [32] is 
marked by arrowhead.
human        1 METSASATASEKQEAKSGILEAAGFPDPGKKASPLVVAAAAAAAVAAQGVPQHLLPPFHA
mouse        1 METSAPAPALEKKEAKSGLLEDSSFPDPGKKACPLAVA----AAVAAHGVPQQLLPAFHA
chicken      1 METSASTVAG-KKEGKGVVLEGDGFTETGKKPTPLAAA----GAAVAQGVPQHIFPAFHA
zebrafish    1 METTSPTSTE-KKELKPSVLDGSSFTDLPKKPSPTTAS----------RAP-HLFSTFHT
human       61 PLPIDMRHQEGRYHYEPHSVHGVHGPPALSGSPVISDISLIRLSPHPAGPGESPFNAPHP
mouse       57 PLPIDMRHQEGRYHYDPHSVHSVHGPPTLSGSPVISDISLIRLSPHPAGPGESPFSAHHP
chicken     56 PLPIDMRHQEGRYHYEPHSIHAIHGPPPLSGSPVISDISLIRLSPHPAGPGESPFSPPHP
zebrafish   49 PIPIDMRHHEGRYHYEPHPLHPMHGPHGLAGSPVISDISLIRLSPHAAATGESPFNPPHP
human      121 YVNPHMEHYLRSVHSSPTLSMISAARGLSPADVAQEHLKERGLFGLPAP--GTTPSDYYH
mouse      117 YVNPHMEHYLRSVHSSPTLSMISAARGLSPADVAHEHLKERGLFSLAAP--GTNPSDYYH
chicken    116 YVTPHMEHYLRSVHGSPTLSVISAARGLSPADVAHEHLKERGLFGLPPPPPGANPTDYYH
zebrafish  109 YVNPHMEHYLRSVHSSPTLSMISAARGLSPAELTHEHLKERSLFGLPPPPPGANPSEYYH
human      179 QMTLVAGHPAPYGDLLMQSGGAASAPHLHDYLNPVDVSRFSSPRVTPRLSRKRALSISPL
mouse      175 QMTLMASHPTPYGDLLMQSGGAASAPHLHDYLNPVDASRFSSPRVTPRLSRKRALSISPL
chicken    176 QMTLMAGHPNPYGDILMQSGGAAGTAHLHEYLSPVDVSRFSSPRVTPRLSRKRALSISPL
zebrafish  169 ---LIASHRSPYGDLLMQTG--AAAAHLPDYMSPVDMSRFPSPRLTPRVSRKRALSISPV
                                                **** 
human      239 SDASLDLQRMIRTSPNSLVAYINNSRSSSAASGSYGHLSAGALSPAFTFPHPINPVAYQQ
mouse      235 SDASLDLQRMIRTSPNSLVAYINNSRSSSAASGSYGHLSAGALSPAFTFPHPINPVAYQQ
chicken    236 SDASIDLQTMIRTSPNSLVAYINNSRSSSAASGSYGHLSAGTISPAFSFPHPINPVTYQQ
zebrafish  224 SDASIDLQTMIRTSPNSLVAYINNSRSSSAASSSYGHLSVGAISPSFTFPHPITPVAYHQ
ź
human      299 ILSQQRGLGSAFGHTPPLIQPSPTFLAQQP--MALTSIN-ATPTQLSSSS-NCLSDTNQN
mouse      295 ILSQQRGLGSAFGHTPPLIQPSPTFLAQQP--MTLTSIS-TMPTQLSSSSSNCLNDANQN
chicken    296 ILTQQRGLSSAFGHTPPLIQPSPTFPPRQH--MAVISVN-PPPAQISSNS-NCISDSSQS
zebrafish  284 LLSQQRGLN-AFGHTPPLLQPSPALSSRQQTLVAAAALNNTTSSSTSSSTADTSTESSQNBMC Molecular Biology 2006, 7:13 http://www.biomedcentral.com/1471-2199/7/13
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locus harbors two alternative 5' noncoding exons, one of
which is highly conserved and has not been described
before. The GLI2 cDNA sequences encompassing exons 1a
and 1b have been deposited in GenBank under accession
numbers DQ004397 and DQ004398, respectively.
The published human GLI2 mRNAs [32] lack about two
thirds of the 3' UTR (in exon 14) when compared to the
mouse Gli2 3' UTR. Comparison with human ESTs [Gen-
Bank: AI822132, BX103004 and AI089685] and genomic
sequence (NT_022135) predicts that the human GLI2
mRNA has a 1822 nt-long 3' UTR containing polyadenyla-
tion signal ATTAAA. This signal and its surrounding
region are well conserved between human and mouse
Gli2  suggesting their requirement for polyadenylation.
This fact is also supported by two GLI2 ESTs that termi-
nate with poly(A) sequences 16 nt downstream of the sig-
nal [GenBank: CA430900 and AI204540].
To confirm the presence of the predicted 3' UTR in the
GLI2 transcripts, RT-PCR with 3' UTR-specific primers was
carried out. Amplification products of the predicted size
(1616 bp) and sequence were obtained for cDNAs derived
from gonadal tissues and two human cell lines (Fig. 3B).
This result shows that human GLI2  mRNA has an
extended 3' UTR as predicted from the bioinformatic anal-
ysis. Another potential polyadenylation signal AATAAA,
located 1119 nt upstream, has been described earlier [32].
However, this may rather represent a cloning arfefact,
since this motif is followed by an A-rich region (AAAAAG-
GAAAGAAAAAA) known to cause oligo-dT mispriming
during cDNA synthesis [37] (Fig. 4). Futhermore, this A-
rich sequence is not conserved in mouse Gli2 gene. The
revised structure of the human GLI2 mRNA containing
complete ORF and its translation is shown in Fig. 4.
Identification of novel alternatively spliced forms of GLI2 
mRNA
We decided to study GLI2 expression in different human
tissues because our gene/mRNA structure analysis pre-
dicted the existence of mRNA alternatively spliced forms.
To determine the expression profile of human GLI2
mRNA, we carried out PCR with primers derived from
exons 2 and 7. PCR products of the expected size (918 bp)
were observed for a number of commercial cDNAs and
different human cell lines. Figure 5A shows that GLI2
mRNA is strongly expressed in the ovary, testis, pancreas,
liver, small intestine and thymus. While low level of
expression was observed for a number of tissues (e.g., pla-
centa, prostate and colon), almost no expression was
detected in heart, brain and peripheral blood leukocytes.
Three 0.9 kb products of identical size obtained from
prostate, ovary and spleen cDNAs were selected for clon-
ing and sequencing. Sequencing of two randomly selected
clones from each cloning confirmed that human GLI2
mRNA contained exons 3–6, as predicted from the gene
Revised structure of the human GLI2 has two alternative 5' noncoding exons and extension in the 3' UTR Figure 3
Revised structure of the human GLI2 has two alternative 5' noncoding exons and extension in the 3' UTR. (A) 
RT-PCR with primers derived from exons 1a-3 and exons 1b-3 are shown (adjoined frames 1a and 1b, respectively). Amplifica-
tion products, 315 bp for exons 1a-3 and 295 bp for exons 1b-3 are shown. The origin of a 400 bp PCR product in 1b-3 reac-
tion of NTera2D1 is unknown. (B) RT-PCR with primers annealing to the 3' UTR. A1616 bp amplification product is shown. 
Complementary DNAs used were derived from tissues and cell lines indicated on top. Control, no cDNA.BMC Molecular Biology 2006, 7:13 http://www.biomedcentral.com/1471-2199/7/13
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Structure of the human GLI2 mRNA and its translation Figure 4
Structure of the human GLI2 mRNA and its translation. Human GLI2 mRNA containing conserved 5' noncoding 
sequence of 69 nt (exon 1a) and complete 3' UTR (1822 nt) are shown. Poly(A) signal is underlined.
1         GGCCACCTGCGTGCTAGAGGCAAACTTTTGTCTCTCTCGGATTGCCACCCAGGACGATGAGCGGCTGAGATGGAGACGTCTGCCTCAGCCACTGCCTCCGAGAAGCAAGAAGCCAAAAGT 
1                                                                               M  E  T  S  A  S  A  T  A  S  E  K  Q  E  A  K  S   
121       GGGATCCTGGAGGCCGCTGGCTTCCCCGACCCGGGTAAAAAGGCCTCTCCTTTGGTGGTGGCTGCAGCGGCAGCAGCAGCGGTAGCTGCCCAAGGAGTGCCGCAGCATCTCTTGCCACCA 
41         G  I  L  E  A  A  G  F  P  D  P  G  K  K  A  S  P  L  V  V  A  A  A  A  A  A  A  V  A  A  Q  G  V  P  Q  H  L  L  P  P   
241       TTCCATGCGCCCCTACCGATTGACATGCGACACCAGGAAGGAAGGTACCATTACGAGCCTCATTCTGTCCACGGTGTGCACGGGCCCCCTGCCCTCAGCGGCAGCCCTGTCATCTCTGAC 
81         F  H  A  P  L  P  I  D  M  R  H  Q  E  G  R  Y  H  Y  E  P  H  S  V  H  G  V  H  G  P  P  A  L  S  G  S  P  V  I  S  D   
361       ATCTCCTTGATCCGGCTTTCCCCGCACCCGGCTGGCCCTGGGGAGTCCCCCTTCAACGCCCCCCACCCGTACGTGAACCCCCACATGGAGCACTACCTCCGTTCTGTGCACAGCAGCCCC 
121        I  S  L  I  R  L  S  P  H  P  A  G  P  G  E  S  P  F  N  A  P  H  P  Y  V  N  P  H  M  E  H  Y  L  R  S  V  H  S  S  P   
481       ACGCTCTCCATGATCTCTGCAGCCAGGGGCCTCAGCCCCGCTGATGTGGCCCAGGAGCACCTTAAGGAGAGGGGACTGTTTGGCCTTCCTGCTCCAGGCACCACCCCCTCAGACTATTAC 
161        T  L  S  M  I  S  A  A  R  G  L  S  P  A  D  V  A  Q  E  H  L  K  E  R  G  L  F  G  L  P  A  P  G  T  T  P  S  D  Y  Y   
601       CACCAGATGACCCTCGTGGCAGGCCACCCCGCGCCCTACGGGGACCTGCTGATGCAGAGCGGGGGCGCTGCCAGCGCACCCCATCTCCACGACTACCTCAACCCCGTGGACGTGTCCCGT 
201        H  Q  M  T  L  V  A  G  H  P  A  P  Y  G  D  L  L  M  Q  S  G  G  A  A  S  A  P  H  L  H  D  Y  L  N  P  V  D  V  S  R   
721       TTCTCCAGCCCGCGGGTGACGCCCCGCCTGAGCCGCAAGCGGGCGCTGTCCATCTCCCCACTCTCAGACGCCAGCCTGGACCTGCAGCGGATGATCCGCACCTCACCCAACTCGCTAGTG 
241        F  S  S  P  R  V  T  P  R  L  S  R  K  R  A  L  S  I  S  P  L  S  D  A  S  L  D  L  Q  R  M  I  R  T  S  P  N  S  L  V   
841       GCCTACATCAACAACTCCCGAAGCAGCTCGGCGGCCAGCGGTTCCTACGGGCATCTGTCAGCGGGTGCCCTCAGCCCAGCCTTCACCTTCCCCCACCCCATCAACCCCGTGGCCTACCAG 
281        A  Y  I  N  N  S  R  S  S  S  A  A  S  G  S  Y  G  H  L  S  A  G  A  L  S  P  A  F  T  F  P  H  P  I  N  P  V  A  Y  Q   
961       CAGATTCTGAGCCAGCAGAGGGGTCTGGGGTCAGCCTTTGGACACACACCACCCCTGATCCAGCCCTCACCCACCTTCCTGGCCCAGCAGCCCATGGCCCTCACCTCCATCAATGCCACG 
321        Q  I  L  S  Q  Q  R  G  L  G  S  A  F  G  H  T  P  P  L  I  Q  P  S  P  T  F  L  A  Q  Q  P  M  A  L  T  S  I  N  A  T   
1081      CCCACCCAGCTCAGCAGCAGCAGCAACTGTCTGAGTGACACCAACCAGAACAAGCAGAGCAGTGAGTCGGCCGTCAGCAGCACCGTCAACCCTGTCGCCATTCACAAGCGCAGCAAGGTC 
361        P  T  Q  L  S  S  S  S  N  C  L  S  D  T  N  Q  N  K  Q  S  S  E  S  A  V  S  S  T  V  N  P  V  A  I  H  K  R  S  K  V   
1201      AAGACCGAGCCTGAGGGCCTGCGGCCGGCCTCCCCTCTGGCGCTGACGCAGGAGCAGCTGGCTGACCTCAAGGAAGATCTGGACAGGGATGACTGTAAGCAGGAGGCTGAGGTGGTCATC 
401        K  T  E  P  E  G  L  R  P  A  S  P  L  A  L  T  Q  E  Q  L  A  D  L  K  E  D  L  D  R  D  D  C  K  Q  E  A  E  V  V  I   
1321      TATGAGACCAACTGCCACTGGGAAGACTGCACCAAGGAGTACGACACCCAGGAGCAGCTGGTGCATCACATCAACAACGAGCACATCCACGGGGAGAAGAAGGAGTTTGTGTGCCGCTGG 
441        Y  E  T  N  C  H  W  E  D  C  T  K  E  Y  D  T  Q  E  Q  L  V  H  H  I  N  N  E  H  I  H  G  E  K  K  E  F  V  C  R  W   
1441      CAGGCCTGCACGCGGGAGCAGAAGCCCTTCAAGGCGCAGTACATGCTGGTGGTGCACATGCGGCGACACACGGGCGAGAAGCCCCACAAGTGCACGTTCGAGGGCTGCTCGAAGGCCTAC 
481        Q  A  C  T  R  E  Q  K  P  F  K  A  Q  Y  M  L  V  V  H  M  R  R  H  T  G  E  K  P  H  K  C  T  F  E  G  C  S  K  A  Y   
1561      TCCCGCCTGGAGAACCTGAAGACACACCTGCGGTCCCACACCGGGGAGAAGCCATATGTGTGTGAGCACGAGGGCTGCAACAAAGCCTTCTCCAACGCCTCGGACCGCGCCAAGCACCAG 
521        S  R  L  E  N  L  K  T  H  L  R  S  H  T  G  E  K  P  Y  V  C  E  H  E  G  C  N  K  A  F  S  N  A  S  D  R  A  K  H  Q   
1681      AATCGCACCCACTCCAACGAGAAACCCTACATCTGCAAGATCCCAGGCTGCACCAAGAGATACACAGACCCCAGCTCTCTCCGGAAGCATGTGAAAACGGTCCACGGCCCAGATGCCCAC 
561        N  R  T  H  S  N  E  K  P  Y  I  C  K  I  P  G  C  T  K  R  Y  T  D  P  S  S  L  R  K  H  V  K  T  V  H  G  P  D  A  H   
1801      GTCACCAAGAAGCAGCGCAATGACGTGCACCTCCGCACACCGCTGCTCAAAGAGAATGGGGACAGTGAGGCCGGCACGGAGCCTGGCGGCCCAGAGAGCACCGAGGCCAGCAGCACCAGC 
601        V  T  K  K  Q  R  N  D  V  H  L  R  T  P  L  L  K  E  N  G  D  S  E  A  G  T  E  P  G  G  P  E  S  T  E  A  S  S  T  S   
1921      CAGGCCGTGGAGGACTGCCTGCACGTCAGAGCCATCAAGACCGAGAGCTCCGGGCTGTGTCAGTCCAGCCCCGGGGCCCAGTCGTCCTGCAGCAGCGAGCCCTCTCCTCTGGGCAGTGCC 
641        Q  A  V  E  D  C  L  H  V  R  A  I  K  T  E  S  S  G  L  C  Q  S  S  P  G  A  Q  S  S  C  S  S  E  P  S  P  L  G  S  A   
2041      CCCAACAATGACAGTGGCGTGGAGATGCCGGGGACGGGGCCCGGGAGCCTGGGAGACCTGACGGCACTGGATGACACACCCCCAGGGGCCGACACCTCAGCCCTGGCTGCCCCCTCCGCT 
681        P  N  N  D  S  G  V  E  M  P  G  T  G  P  G  S  L  G  D  L  T  A  L  D  D  T  P  P  G  A  D  T  S  A  L  A  A  P  S  A   
2161      GGTGGCCTCCAGCTGCGCAAACACATGACCACCATGCACCGGTTCGAGCAGCTCAAGAAGGAGAAGCTCAAGTCACTCAAGGATTCCTGCTCATGGGCCGGGCCGACTCCACACACGCGG 
721        G  G  L  Q  L  R  K  H  M  T  T  M  H  R  F  E  Q  L  K  K  E  K  L  K  S  L  K  D  S  C  S  W  A  G  P  T  P  H  T  R   
2281      AACACCAAGCTGCCTCCCCTCCCGGGAAGTGGCTCCATCCTGGAAAACTTCAGTGGCAGTGGGGGCGGCGGGCCCGCGGGGCTGCTGCCGAACCCGCGGCTGTCGGAGCTGTCCGCGAGC 
761        N  T  K  L  P  P  L  P  G  S  G  S  I  L  E  N  F  S  G  S  G  G  G  G  P  A  G  L  L  P  N  P  R  L  S  E  L  S  A  S   
2401      GAGGTGACCATGCTGAGCCAGCTGCAGGAGCGCCGCGACAGCTCCACCAGCACGGTCAGCTCGGCCTACACCGTGAGCCGCCGCTCCTCCGGCATCTCCCCCTACTTCTCCAGCCGCCGC 
801        E  V  T  M  L  S  Q  L  Q  E  R  R  D  S  S  T  S  T  V  S  S  A  Y  T  V  S  R  R  S  S  G  I  S  P  Y  F  S  S  R  R   
2521      TCCAGCGAGGCCTCGCCCCTGGGCGCCGGCCGCCCGCACAACGCGAGCTCCGCTGACTCCTACGACCCCATCTCCACGGACGCGTCGCGGCGCTCGAGCGAGGCCAGCCAGTGCAGCGGC 
841        S  S  E  A  S  P  L  G  A  G  R  P  H  N  A  S  S  A  D  S  Y  D  P  I  S  T  D  A  S  R  R  S  S  E  A  S  Q  C  S  G   
2641      GGCTCCGGGCTGCTCAACCTCACGCCGGCGCAGCAGTACAGCCTGCGGGCCAAGTACGCGGCAGCCACTGGCGGCCCCCCGCCCACTCCGCTGCCGGGCCTGGAGCGCATGAGCCTGCGG 
881        G  S  G  L  L  N  L  T  P  A  Q  Q  Y  S  L  R  A  K  Y  A  A  A  T  G  G  P  P  P  T  P  L  P  G  L  E  R  M  S  L  R   
2761      ACCAGGCTGGCGCTGCTGGACGCGGCCGAGGGCACGCTGCCCGCCGGCTGCCCACGCCCACTGGGGCCGCGGCGTGGCAGCGACGGGCCGACCTATGGCCACGGCCACGCGGGGGCTGCG 
921        T  R  L  A  L  L  D  A  A  E  G  T  L  P  A  G  C  P  R  P  L  G  P  R  R  G  S  D  G  P  T  Y  G  H  G  H  A  G  A  A   
2881      CCCGCCTTCCCCCACGAGGCTCCAGGCGGCGGAACCAGGCGGGCCAGCGACCCTGTGCGGCGGCCCGATGCCCTGTCCCTGCCGCGGGTGCAGCGCTTCCACAGCACCCACAACGTGAAC 
961        P  A  F  P  H  E  A  P  G  G  G  T  R  R  A  S  D  P  V  R  R  P  D  A  L  S  L  P  R  V  Q  R  F  H  S  T  H  N  V  N   
3001      CCCGGCCCGCTGCCGCCCTGTGCCGACAGGCGAGGCCTCCGCCTGCAGAGCCACCCGAGCACCGACGGCGGCCTGGCCCGCGGCGCCTACTCGCCCCGGCCGCCTAGCATCAGCGAGAAC 
1001       P  G  P  L  P  P  C  A  D  R  R  G  L  R  L  Q  S  H  P  S  T  D  G  G  L  A  R  G  A  Y  S  P  R  P  P  S  I  S  E  N   
3121      GTGGCGATGGAGGCCGTGGCGGCAGGAGTGGACGGCGCGGGGCCCGAGGCCGACCTGGGGCTGCCGGAGGACGACCTGGTGCTTCCAGACGACGTGGTGCAGTACATCAAGGCGCACGCC 
1041       V  A  M  E  A  V  A  A  G  V  D  G  A  G  P  E  A  D  L  G  L  P  E  D  D  L  V  L  P  D  D  V  V  Q  Y  I  K  A  H  A   
3241      AGTGGCGCTCTGGACGAGGGCACCGGGCAGGTGTATCCCACGGAAAGCACTGGCTTCTCTGACAACCCCAGACTACCCAGCCCGGGGCTGCACGGCCAGCGCAGGATGGTGGCTGCGGAC 
1081       S  G  A  L  D  E  G  T  G  Q  V  Y  P  T  E  S  T  G  F  S  D  N  P  R  L  P  S  P  G  L  H  G  Q  R  R  M  V  A  A  D   
3361      TCCAACGTGGGCCCCTCCGCCCCTATGCTGGGAGGATGCCAGTTAGGCTTTGGGGCGCCCTCCAGCCTGAACAAAAATAACATGCCTGTGCAGTGGAATGAGGTGAGCTCCGGCACCGTA 
1121       S  N  V  G  P  S  A  P  M  L  G  G  C  Q  L  G  F  G  A  P  S  S  L  N  K  N  N  M  P  V  Q  W  N  E  V  S  S  G  T  V   
3481      GACTCCCTGGCCAGCCAGGTGAAGCCTCCACCCTTTCCTCAGGGCAACCTGGCGGTGGTGCAGCAGAAGCCTGCCTTTGGCCAGTACCCGGGCTACAGTCCGCAAGGCCTACAGGCTAGC 
1161       D  S  L  A  S  Q  V  K  P  P  P  F  P  Q  G  N  L  A  V  V  Q  Q  K  P  A  F  G  Q  Y  P  G  Y  S  P  Q  G  L  Q  A  S   
3601      CCTGGGGGCCTGGACAGCACGCAGCCACACCTGCAGCCCCGCAGCGGAGCCCCCTCCCAGGGCATCCCCAGGGTAAACTACATGCAGCAGCTGCGACAGCCAGTGGCAGGCAGCCAGTGT 
1201       P  G  G  L  D  S  T  Q  P  H  L  Q  P  R  S  G  A  P  S  Q  G  I  P  R  V  N  Y  M  Q  Q  L  R  Q  P  V  A  G  S  Q  C   
3721      CCTGGCATGACTACCACTATGAGCCCCCATGCCTGCTATGGCCAAGTCCACCCCCAGCTGAGCCCCAGCACCATCAGTGGGGCCCTCAACCAGTTCCCCCAATCCTGCAGCAACATGCCA 
1241       P  G  M  T  T  T  M  S  P  H  A  C  Y  G  Q  V  H  P  Q  L  S  P  S  T  I  S  G  A  L  N  Q  F  P  Q  S  C  S  N  M  P   
3841      GCCAAGCCAGGGCATCTGGGGCACCCTCAGCAGACAGAAGTGGCACCTGACCCCACCACGATGGGCAATCGCCACAGGGAACTTGGGGTCCCCAATTCAGCCCTGGCTGGAGTGCCGCCA 
1281       A  K  P  G  H  L  G  H  P  Q  Q  T  E  V  A  P  D  P  T  T  M  G  N  R  H  R  E  L  G  V  P  N  S  A  L  A  G  V  P  P   
3961      CCTCACCCAGTCCAGAGCTACCCACAGCAGAGCCATCACCTGGCAGCCTCCATGAGCCAGGAGGGCTACCACCAGGTCCCCAGCCTTCTGCCTGCCCGCCAGCCTGGCTTCATGGAGCCC 
1321       P  H  P  V  Q  S  Y  P  Q  Q  S  H  H  L  A  A  S  M  S  Q  E  G  Y  H  Q  V  P  S  L  L  P  A  R  Q  P  G  F  M  E  P   
4081      CAAACAGGCCCGATGGGGGTGGCTACAGCAGGCTTTGGCCTAGTGCAGCCCCGGCCTCCCCTCGAGCCCAGCCCCACTGGCCGCCACCGTGGGGTACGTGCTGTGCAGCAGCAGCTGGCC 
1361       Q  T  G  P  M  G  V  A  T  A  G  F  G  L  V  Q  P  R  P  P  L  E  P  S  P  T  G  R  H  R  G  V  R  A  V  Q  Q  Q  L  A   
4201      TACGCCAGGGCCACAGGCCATGCCATGGCTGCCATGCCGTCCAGTCAGGAAACAGCAGAGGCTGTGCCCAAGGGAGCGATGGGCAACATGGGGTCGGTGCCTCCCCAGCCGCCTCCGCAG 
1401       Y  A  R  A  T  G  H  A  M  A  A  M  P  S  S  Q  E  T  A  E  A  V  P  K  G  A  M  G  N  M  G  S  V  P  P  Q  P  P  P  Q   
4321      GACGCAGGTGGGGCCCCGGACCACAGCATGCTCTACTACTACGGCCAGATCCACATGTACGAACAGGATGGAGGCCTGGAGAACCTCGGGAGCTGCCAGGTCATGCGGTCCCAGCCACCA 
1441       D  A  G  G  A  P  D  H  S  M  L  Y  Y  Y  G  Q  I  H  M  Y  E  Q  D  G  G  L  E  N  L  G  S  C  Q  V  M  R  S  Q  P  P   
4441      CAGCCACAGGCCTGTCAGGACAGCATCCAGCCCCAGCCCTTGCCCTCACCAGGGGTCAACCAGGTGTCCAGCACTGTGGACTCCCAGCTCCTGGAGGCCCCCCAGATTGACTTCGATGCC 
1481       Q  P  Q  A  C  Q  D  S  I  Q  P  Q  P  L  P  S  P  G  V  N  Q  V  S  S  T  V  D  S  Q  L  L  E  A  P  Q  I  D  F  D  A   
4561      ATCATGGATGATGGCGATCACTCGAGTTTGTTCTCGGGTGCTCTGAGCCCCAGCCTCCTCCACAGCCTCTCCCAGAACTCCTCCCGCCTCACCACCCCCCGAAACTCCTTGACCCTGCCC 
1521       I  M  D  D  G  D  H  S  S  L  F  S  G  A  L  S  P  S  L  L  H  S  L  S  Q  N  S  S  R  L  T  T  P  R  N  S  L  T  L  P   
4681      TCCATCCCCGCAGGCATCAGCAACATGGCTGTCGGGGACATGAGCTCCATGCTCACCAGCCTCGCCGAGGAGAGCAAGTTCCTGAACATGATGACCTAGAGGCCCGAGCGCCTGGTGCTG 
1561       S  I  P  A  G  I  S  N  M  A  V  G  D  M  S  S  M  L  T  S  L  A  E  E  S  K  F  L  N  M  M  T  *   
4801      AGTGCACCCGGAGGGGTCATCGCTGCCCAGAGCCTGGGGATTCCAGCTGTCTTGTCTTTTTCCAAAAAAGTGTTAAATAGGCTTGAGGGGTTGTTGCGCAATGGCCGCTTCAGATGACAG 
4921      ATGTTGTAAGAGAAGGTTTATGGGCATCCTCTCTGGTCTTTTGGATTATTCCTCAGAACAATGAAAAAAGTCTCCATAGGACAGGAAGGAATGCAAAACTCATTTACACAGTGCTTTCCA 
5041      GCCTTTGGTGCTTACAGGACCGCGCTGTTCCGGCTTCTTCACGGCTGACATTCGGCTAACGAGGGATTACTTTGGCCAAAACCTTTCAAAGGATATGCAGAAAGATGGTAGGGAGCATTT 
5161      GGGTTTGAATCTGAATGCTATACTGGATACTCTGCTCCGGAAAGATGAGCTTTTTATTCTACTACTTGGAAGGAAAAGGAATTCCTGGTCCACCTGAATTCCTCTATGAAGCCTAACTCT 
5281      TGAGGTCTCTAACATACCTTGTCATAGAGGAAAAGCACAGATTATACCTGGATGATTCAGGAGCACATTCTGATTCCAGGTTTGGTAGAGCTGGCTCTTCTACTCCGTAAAGCCGAGTCT 
5401      GGGACTGGCAGCCCATCCAAGTGTATATGAATGAATAAAGCATCCAAGTATATATGAATGAATAAAGTATGTAAGTATCACCAGAAAAAGGAAAGAAAAAATGTACTCCTTGGGGCAAGC 
5521      CCAGAAGCTGCCCTGGCCTCTCCAGACCGTGTTTACAGTGTTTGCATGTAGAATGTAGCCCTTCCTGAAAAGAAGACTTGTTTCTAAATACCTCGGGGCTGCTGGAGCCGCTGTGGGTTA 
5641      GGGATGGACTGAGGCCTCGAGGAGTGAGGGTGCACCCGGGGCCCAGCCTCAGGCTGCCCTAGGGATCTCTCAGTAGGAAGAGGAAGTTGCGTGTTTACCCAATCCTGTTTCTCCAATGCA 
5761      ACGTCCACCCACTTTACCACCAAAAACTCCAGGGCCTGACGGCAGCCCGGTCCCCCAGCACTCACCAGCAGCCCAGTGTTCTCCACCAAGCCACAGTGTGCATGCCTGGTATCCTCCGGA 
5881      TTCCCTTCCTTCTGCCCGCTGAGTCACTGGGCAGAGAATGATGACATGTGTAGGTGGTGTGGTTGGGGGTGGAAAGGGGAAGGGGTTGATCCTCAGGACTCTGAGGGAGCATCGTTGAAT 
6001      TTTCCTGTTCAGTGTGACCAAGACCCACCTGGAAATGGAATTTGGAACTGGCTTCAGGAGACATCATTCCTGAACACACTGTAGGGTGAATTGGTGCATCTTCCCCACCATACACACACA 
6121      CACACACACACACACACACACACACACACACACACCCCAAACCTTTTCATGGGGAATGTGTGGCAACCTTGCCAAACAGCACCACTCAGAGTGTGACTCTGACTGTGACCTTGGCCTTAA 
6241      TGAGGAACTTCTTAGGAGAGTTTGAGGACAAGGCCAACATCGTCATCTGGGCTCGCTGCGTCCCAGCACATCAAACTCTGTCCAGAGACAAGGCCAACTGCAAATGAAAGCCAGGGAACA 
6361      TTGCTAAGGGTCTGTGGCTCTGTGGTGGTGTTCATCGCCTTCCTGAGATAGGATTTCCCTTGCCAGTCCCAACCTGTATATATTCTGTACAGAAGACATCCCTGAATATACTGTAGGTGA 
6481      GTCGTCCAGCCAAATTTATATCTCCAAAACATTTTTAGCTTTTTCTACATGCTATGAATTGAGATGACATGCTCAACTTGTAAATAAGTCTTTTTGTACATTAAAAAAGTAATTTTTTCA 
6601      T BMC Molecular Biology 2006, 7:13 http://www.biomedcentral.com/1471-2199/7/13
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structure (Fig. 1). The cloned sequence encompassing
exons 2–7 is available in GenBank under accession
number AY493737.
We also detected three minor RT-PCR products corre-
sponding to GLI2 transcript variants approximately 100
and 400 bp shorter than GLI2 mRNA described above.
These transcripts were present exclusively in ovary, testis
and different cell lines (Fig. 5). Sequencing of 2–3 individ-
ual cDNA clones (RT-PCR cloning from ovary, testis and
NTera2D1 cells) corresponding to these variants showed
that they represented three different types of alternative
splicing (Fig. 6). Type I clones had exon 3 spliced to exon
6. Type II clones showed similar skipping of exons 4 and
5, but had a different splice acceptor site between exons 6
and 7. Type III clones had exon 2 spliced to exon 4. Rep-
resentative sequences of each type of splicing are available
in GenBank under accession numbers AY493738,
AY493739 and DQ004396. These results show that in the
human tissues, GLI2 mRNA may be represented by three
different alternatively spliced forms. For all GLI2 mRNA
alternatively spliced forms described, the major ORF start-
ing from the exon 2 with the sequence METSA (Fig. 6) was
followed by premature termination codon. Thus, transla-
tion from the alternatively spliced forms is possible only
from downstream initiator codons in frame with the main
ORF.
Alternative splicing of GLI2 mRNA is responsible for the 
synthesis of GLI2 protein isoforms with different activities
We hypothesized that splicing within the first seven exons
may be involved in the exclusion or inclusion of the
repressor domain of GLI2 protein. To test if alternatively
spliced isoforms GLI2∆3 and GLI2∆4–5 can produce func-
tional proteins, the corresponding cDNAs were subcloned
into pCDNA3 expression vector and tested for the produc-
tion of proteins using translation in vitro. Fig. 7A shows
that GLI2∆4–5 and GLI2∆3 generate N-terminally trun-
cated proteins with approximate sizes 155 kDa and 160
kDa, respectively. Because GLI2  ORF starting from the
AUG located in exon 2 ended with premature termination
codon, translation of the alternatively spliced forms of
Tissue-specificity of GLI2 mRNA and its alternatively spliced forms Figure 5
Tissue-specificity of GLI2 mRNA and its alternatively spliced forms. Southern blot analysis of the PCR products 
amplified from cDNAs derived from (A) normalized multiple tissue panels and (B) different cell lines (indicated on top of the 
panel) using GLI2-specific primers derived from exons 2 and 7. The products were hybridized with a 918 nt-riboprobe encom-
passing GLI2 exons 2–7. Bars on the right indicate sizes of PCR products corresponding to GLI2 mRNA and its alternatively 
spliced forms GLI2∆3 and GLI2∆4–5 (0.9, 0.8 and 0.5 kb, respectively). A shorter and longer exposure were used to determine 
the presence of minor transcripts corresponding to GLI2∆3 (0.8 kb) in ovary and testis (panel A). Note the complex pattern of 
alternatively spliced products observed for cell lines (panel B) that is most likely due to promiscuous splicing (not analyzed in 
detail). Control, no cDNA.BMC Molecular Biology 2006, 7:13 http://www.biomedcentral.com/1471-2199/7/13
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GLI2 was possible only from downstream AUG codons
(Fig. 7B). The low protein yield obtained in the case of
GLI2∆4–5 was apparently due to inefficient translation
initiation.
To determine the activation or repression effect of pro-
teins produced from GLI2  mRNA and its alternatively
spliced forms, each construct (GLI2fl,  GLI2∆3 and
GLI2∆4–5) was co-transfected with 12XGLIluc reporter
plasmid into COS-7 cells. In this transactivation assay,
GLI2∆3 activator effect was comparable to that of the
GLI2fl (Fig. 8). However, GLI2∆4–5 showed about 10-
fold increase in the reporter activity, suggesting that the
enhanced activation was due to the loss of repressor activ-
ity, i.e. excision of repressor domain (or part of it) by alter-
native splicing.
Transactivation experiments repeated with PTCH pro-
moter, containing two GLI2 binding sites [19], yielded
similar results, although in this case about 3-fold
enhancement was detected (data not shown). Transcrip-
tional activity of all constructs was significantly sup-
pressed by co-transfection with SUFU construct indicating
that SUFU-binding domain, SYGH, encoded by exon 6
was intact in all constructs used. These data show that
both GLI2∆4–5 and GLI2∆3 generate alternatively spliced
forms that can be translated into active proteins. Differ-
ence in their activities is most likely caused by the N-ter-
minal sequence
MEHYLRSVHSSPTLSMISAARGLSPADVAQEHLKERGLFG
LPAPGTTPSDYYHQMTLVAGHPAPYGDLLMQSGGAAS-
APHLHDYLNPVD, encoded by GLI2∆3 and missing in
GLI2∆4–5. We suspected that this 89 aa region (or part of
it, depending on translation initiation site used) might
contain critical sequences required for GLI2 repressor
activity. To map these sequences more precisely, we
deleted the first 32 aa of the N-terminal sequence encoded
of GLI2∆3 by generating GLI2∆3BB. Expression of this
construct most likely produces an N-terminally truncated
protein with translation initiation from the sequence
Alternative splicing in the 5' end of GLI2 mRNA Figure 6
Alternative splicing in the 5' end of GLI2 mRNA. Exons corresponding to cloned and/or sequenced splice variants are 
marked by bold lines. Exon and intron splice junction sequences are designated by upper and lower case letters, respectively. 
Alternatively spliced forms I-III arising via exon skipping and different exon 6–7 junction usage (described in this study) are 
compared with the previously published sequence (Type IV) [32]. For each alternatively spliced form, GenBank accession 
number is shown on the right. Translation of these sequences initiated from ATG codon located in exon 2 (METSA) termi-
nates with premature termination codons (PTC). Location of initiator codon described previously [32] is shown in exon 7 (M). 
Location of the SUFU binding site (SYGH) in exon 6 is shown.
8-14
M METSA
7 23 4 5 16
SYGH
AY493738
PTC
PTC
Type II 
GLI2ǻ4-5
Type I 
GLI2ǻ4-5
…TGTGCACGGgtaagtcct… …atcccacagTGTCCCGTT…
…CCTCAG|CCTTCA…
Type IV 
GLI2ǻ3-6
…CCCAAGGAGgtactttct…
…gttgcagCCCAGCCTT…
…TGTGCACGGgtaagtcct… …atcccacagTGTCCCGTT…
PTC
…CCCAAGGAGgtacttt…
…tctgcagGCCCCCTGC…
AY493739
DQ004396 Type III 
GLI2ǻ3
PTC
NM_030379-81BMC Molecular Biology 2006, 7:13 http://www.biomedcentral.com/1471-2199/7/13
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MTLVAG located 54 aa downstream with respect to the
GLI2∆3 translation initiation. This prediction was also
supported by GLI2∆3BB translation in vitro (data not
shown). In the transactivation assay, GLI2∆3BB showed
enhanced activation reaching about 70% level of that of
GLI2∆4–5 (Fig. 8), suggesting that 54 aa encoded by exons
4 and 5 were critical for the repressor activity. In summary,
our results show that alternative splicing involved in the
deletion of the repressor domain encoded by exons 4 and
5 is responsible for the enhanced activation of GLI2 pro-
tein.
Discussion
In this study we describe the structure of the human GLI2
gene and its expression in different human tissues. A
detailed comparison between human and mouse Gli2
structures allowed us to revise the structure of human
GLI2 [32,33] by introducing a novel noncoding exon (1a)
and extending the 3' UTR. Our data support the earlier
finding of Roessler et al. [33] that human GLI2 contains
exons 3–6 encoding repressor domain. This domain is
highly conserved in evolution and has a major impact on
the modulation of GLI2 transcriptional activity. As
inferred from the studies on Ci and Gli3, the most likely
mechanism that separates repressor and activator
domains is proteolytic processing [13,15]. Here we show
for the first time that in addition to proteolytic processing,
alternative splicing may be another important regulatory
mechanism which causes deletion of the major part of
repressor domain and thus is responsible for the
enhanced activation of human GLI2. In theory, transla-
tion from the downstream initiator codon observed in the
alternatively spliced form GLI2∆4–5 is rather inefficient.
Nevertheless, the activation effect observed (about 10-
fold) is significant, although less protein is produced from
GLI2∆4–5 compared to GLI2fl.
In vitro translation of the GLI2 mRNA and its alternatively spliced forms Figure 7
In vitro translation of the GLI2 mRNA and its alternatively spliced forms. (A) SDS-gel analysis of [35S]-methionine 
labeled products translated with rabbit reticulocyte lysate. Constructs used are indicated on the top. Molecular weight marker 
positions are shown on the left. (B) Schematic representation of the translation products of the splice forms (shown on the 
right, with predicted molecular weight in parenthesis). mRNAs are shown by bold lines and their translation products are 
drawn by solid boxes. Open box represents translation in a different reading frame. The predicted N-terminal sequences (5 aa) 
are shown.BMC Molecular Biology 2006, 7:13 http://www.biomedcentral.com/1471-2199/7/13
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Previous studies of others [12] showed that the removal of
the N-terminal region (residues 1–279 encoded by exons
2–6) resulted about 10-fold enhancement of the tran-
scriptional activity of mouse Gli2. Similarly, expression of
truncated human GLI2 lacking N-terminal 328 aa,
encoded by exons 2–6, demonstrated substantial increase
(about 10 to 30-fold) in transcriptional activity of GLI2
[33]. Also, cotransfection experiments showed that the
repressor domain encoded by exons 2–6 is involved in the
dominant-negative activity of disease-associated GLI2
mutants [33].
Taken together, all these results show that the N-terminal
region of either mouse or human GLI2 contains a domain
with transcriptional repressor activity. While all these
results suggest that repressor domain of mouse and
human GLI2 is encoded by exons 2–6, our results show
the the removal of exons 4–5 alone can affect transcrip-
tional activity of GLI2. Additional mapping of the repres-
sor activity showed that a critical 54 aa-long sequence is
encoded by exons 4 and 5. Therefore, our results strongly
suggest that alternative splicing may be involved in the
regulation of the synthesis of GLI2 proteins with or with-
out repressor activities. Interestingly, we have detected
several Gli2 mRNA splice forms, including Gli2∆4–5 and
Gli2∆3 in mouse embryos, indicating that alternative
splicing of Gli2  pre-mRNA may be evolutionarily con-
served (Hanna Tulmin, Pille Pata, PK and IP, unpublished
data).
Previous studies [6,32] have suggested that human GLI2
mRNA may exist in at least four different isoforms, which
can be detected in tumor cell lines or tissues. Here we have
analyzed alternative splicing in the 5' region of GLI2,
encompassing exons 1–7, in normal human tissues. We
found that exons 3–5 are involved in the alternative splic-
ing and corresponding alternatively spliced forms (skip-
ping exons 3 and 4–5) were exclusively found in adult
ovarian and testicular tissues, raising a question about
potential role of GLI2 acting solely as an activator of germ
cell development. It should be noted, that knock-in mice
expressing full-length Gli2 cDNA from the endogenous
Gli2 locus are normal and viable, arguing against the role
of alternative transcripts in normal mouse development
[25]. Our attempts to detect alternatively spliced forms of
GLI2 mRNA, in which exons 2 and 7 were spliced together
(GLI2∆3–6), as described earlier [32], have not been suc-
cessful. It is likely that different alternatively spliced forms
are expressed in tumor cell lines or tissues. However their
origin remains unclear. It is also important to note that a
highly conserved motif SYGH involved in the interaction
of GLI2 with SUFU [21] is encoded by exon 6. Because
this exon is lost in the spliced form GLI2∆3–6, it is possi-
ble that its expression gives rise to a GLI2 protein escaping
repression and/or sequestration effects of SUFU. We
believe that the loss of SUFU binding site of GLI2 protein
may have important implications in the regulation of Shh
signaling pathway. However, to prove this possibility,
additional experiments are required.
We have shown that human GLI2 contains two alternative
noncoding 5' exons 1a and 1b. This feature typically sug-
gests the usage of alternative promoters and thus adds
another layer of complexity to the regulation of human
GLI2. It remains to be explored how these promoters can
influence the biological function of human GLI2.
Conclusion
We report here the revised structure of human GLI2 gene.
We present evidence that alternative splicing regulates the
transcriptional activity of GLI2. Our data suggest that in
addition to proteolytic processing, alternative splicing
may be another important regulatory mechanism for the
modulation of repressor and activator properties of GLI2
protein.
Methods
Biocomputational analysis
Comparison of the mouse and human GLI2  genomic
DNAs and mRNAs was carried out by SPIDEY [38]. Repet-
itive DNA elements were identified by RepeatMasker
(A.F.A. Smit and P. Green, unpublished data). Previously
published Gli2 mRNA sequences were extended at their 5'
and/or 3' termini using overlapping expressed sequence
tags (ESTs) derived from the searches of GenBank data-
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Expression of the GLI2 and its alternatively spliced 
forms produces protein isoforms with different activ-
ities. Transactivation assay with luciferase reporter plasmid 
(12XGLIluc), various GLI2 and SUFU constructs was carried 
out as described in Methods section using COS-7 cell line.
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base using MEGABLAST [39]. The extended mRNA struc-
tures were mapped to the genomic structure by SPIDEY.
All translations and mRNA/cDNA sequence comparisons
were done with DNAMAN Version 4.0 (Lynnon BioSoft).
Mouse, chicken and zebrafish Gli2 protein sequences
were derived from databases [GenBank: XP_136212,
XP_422086, and AAD18135].
Accession numbers
Sequence data described in this study were deposited into
GenBank under accession numbers AY493737,
AY493738, AY493739, DQ004396, DQ004397, and
DQ004398.
Reverse transcription, DNA amplification and cloning
PCR of the normalized multiple tissue cDNA (MTC) pan-
els I-II (BD Biosciences) and cDNAs prepared from differ-
ent human cell lines (oligo dT and random priming) was
carried out with primers designed into exons 2 (GCCTC-
CGAGAAGCAAGAAGC) and exon 7 (TGGTGTGTGTC-
CAAAGGCTGA) using the following temperature profile:
95°C 30 s, 55°C 30 s and 72°C 1 min for 35 cycles. The
following human cell lines were used: neuroblastomas
SH-SY5Y (ATCC Number: CRL-2266) and SK-N-SH
(ATCC Number: HTB-11); mammary gland adenocarci-
noma MDA-MB-231 (ATCC Number: HTB-26); glioma
G168P44 (a gift from Andres Veske); teratocarcinoma
NTera2D1 (ATCC Number: CRL-1973); embryonic kid-
ney HEK293 (ATCC Number: CRL-1573). All PCR prod-
ucts encompassing GLI2 exons 2–7 or their alternatively
spliced forms were analyzed by agarose gel electrophore-
sis, transferred to Hybond N+ membrane (Amersham Bio-
sciences) and hybridized with a 918 nt 32P-labeled
riboprobe prepared from the cloned GLI2 cDNA contain-
ing exons 2–7 [40]. After gel-elution, PCR products were
cloned into SmaI site of the pBluescript SK+ vector (Strat-
agene) by blunt-end ligation. Recombinant DNAs were
isolated and both strands of inserts were sequenced using
T3 and T7 primers.
Cloning of the human GLI2 cDNA containing complete
ORF was carried out as follows. First strand cDNA was
synthesized with SuperScript III Reverse Transcriptase
(Invitrogen) using total RNA isolated from human terato-
carcinoma cell line NTera2D1 (ATCC Number: CRL-
1973). PCR amplification of cDNA was carried out in two
separate experiments. A 2481 bp 5' terminal fragment was
generated with primers D3 (TGCTGCTTTACCGACA-
CATC) and R6A (GGAGGAGCGGCGGCTCACG), and a
2290 bp 3' terminal fragment was generated with primers
D6 (GGCATCTCCCCCTACTTCTC) and Rev3 (TCTAGGT-
CATCATGTTCAGGA). PCR conditions were the same as
in MTC panel amplification reaction (see above), except
that annealing temperature was 55°C and extension time
4 min. Both fragments obtained were cloned into SmaI
site of the pBluescript SK+ vector. To facilitate blunt-end
cloning into expression vector, cloned 5' and 3' terminal
fragments together with regions derived from multiple
cloning site of the vector were amplified (10 PCR cycles)
with a combination of T7 promoter primer and R6A, and
T3 promoter primer and D6, respectively. Both gene-spe-
cific primers were phosphorylated at 5' termini. The
obtained 5' and 3' fragments were joined by blunt-end
ligation, digested with HindIII and XbaI and cloned into
HindIII-XbaI linearized pCDNA3 expression vector. The
final construct, GLI2fl, contained complete GLI2 ORF and
its structure was verified by sequencing. Constructs
GLI2∆3 and GLI2∆4–5 were generated by replacing a
region flanked by BamHI and BglII sites (encompassing
exons 2–9) in GLI2fl with fragments obtained from alter-
natively spliced forms (∆3 and ∆4–5) cloned in pBlue-
script SK+ vector. Cloning of alternatively spliced forms
by RT-PCR was analogous to that described above, except
that the following primers derived from exons 2 and 9
were used: GCCTCCGAGAAGCAAGAAGC and ACCT-
CAGCCTCCTGCTTACA. Construct GLI2∆3BB was gener-
ated from GLI2∆3 by deleting a 257 bp fragment with
restriction enzymes BamHI and BspT1 and blunting the
ends with Klenow polymerase. All constructs were verified
by DNA sequencing.
To analyze expression of alternative first exons 1a and 1b
in human tissues and cell lines, PCR was carried out with
the forward primers annealing to exon 1a (GGCCACCT-
GCGTGCTAGAG) or 1b (CCGACACATCAAAGAGCAAG-
GATTG) and the reverse primer annealing to exon 3
(ACCGTGGACAGAATGAGGCT). We used the first-strand
cDNAs from human ovary and testis (BD Biosciences),
and cDNAs derived from NTera2D1 and HEK293 cell
lines. These cDNAs were synthesized with Superscript III
using total RNA. Amplification was conducted at 95°C 30
s, 55°C 30 s and 72°C 1 min for 40 cycles.
To confirm the presence of the predicted 3' UTR in GLI2
transcripts, RT-PCR with primers TTTATGGGCATC-
CTCTCTGGT and GCATGTCATCTCAATTCATAGCA was
used for the amplification of a 1616 bp fragment derived
from a region located 27 bp upstream to the polyadenyla-
tion signal (ATTAAA). The amplification profile used was
identical to that described for exons 1a/1b-3 (above),
except that the extension step was 2 min. To exclude the
amplification from genomic DNA, RT minus reaction was
used as a negative control.
In vitro translation and transactivation assay
In vitro translation assays were carried out using TNT®
Quick Coupled Transcription/Translation Systems
(Promega). COS-7 cell line was used for the luciferase
reporter assay. Transfection of cells plated on 24-well
plates reaching cell density about 80% was carried outBMC Molecular Biology 2006, 7:13 http://www.biomedcentral.com/1471-2199/7/13
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with 0.5 µg of GLI2 construct (GLI2fl, GLI2∆3, GLI2∆3BB
and GLI2∆4–5) 0.3 µg of SUFU DNA or empty vector, 0.1
µg 12XGLIluc reporter plasmid and 0.1 µg of pCMV-β-gal
using FuGene (Roche) according to the manufacturer's
instructions at DNA to FuGene ratio of 1:3 (w/v). SUFU
and reporter plasmid used in this study have been
described previously [19]. pCDNA3 plasmid DNA was
added to the transfections as needed to achieve the total
amount of plasmid DNA per transfection. After 24 h the
medium was replaced with low serum media (0.5% calf
serum) and cells were incubated for an additional 24 h.
Subsequently cells were lysed and luciferase activity was
measured with a luciferase kit from Tropix (Bedford)
according to the manufacturer's instructions using an
Ascent Fluoroscan combined fluori- and luminometer
(Thermo Lab-Systems). Luciferase activities were normal-
ized with respect to parallel β-gal activities, to correct for
differences in transfection efficiency. β-gal assays were
performed using Galacto-Light/Galacto-Light Plus Sys-
tems (Tropix) according to the manufacturer's instruc-
tions. All experiments were repeated at least three times.
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